Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
study id #: NCT04644393
condition: Spinal Muscular Atrophy
status: Not yet recruitingpurpose:
The Motor Function Measure (MFM), a reliable tool assessing motor function and its progression in most neuromuscular diseases, is widely used in France in many teams. It can be used regardless of the severity of the motor impairment or the ambulatory status of the patient, allowing its use throughout the whole follow-up period of the patient, even in case of the loss of walking. Two versions of the MFM exist, one composed of 32 items validated for patients from 6 years old (MFM-32) and a shorter version composed of 20 items validated for patients between 2 and 6 years old (MFM-20).
In order to show the possible use of MFM-20 as early as the age of 2 years to validly and reliably monitor the evolution of the motor function of children treated with Nusinersen, we propose in this project to study the sensitivity to treatment-induced change of MFM-20 and the validity of the scale in this population.
last updated: February 04, 2022
start date: November 2020
estimated completion: March 2021
last updated: November 25, 2020
size / enrollment: 40
- MFM-20 responsiveness
The MFM-20 sensitivity to change indexes considered will be the effect amplitude and the Standardized Response Mean (SRM).
- At least 6 Months after the first MFM-20 assessment, and at maximum 24 months
• Eligible Sexes: all
Boys and girls with Type 1 or 2 Spinal Muscular Atrophy, genetically confirmed
Aged 2 to 6 years old
Treated by Nusinersen for at least two months
With at least 3 MFM-20 repeated measures, and with adelay minimum between the first and the last MFM-20 of 6 months
With parental assent
exclusion criteria: Criteria:
- Patients with associated cognitive impairment making impossible evaluation of motor function
Patients participating to a clinical study with a potential effect on their motor function.
Magnetic Resonance Reveals Mitochondrial Dysfunction and Muscle Remodelling in Spinal Muscular AtrophyGenetic therapy has changed the prognosi...
Cell-Penetrating Peptide-Conjugated Morpholino Rescues SMA in a Symptomatic Preclinical ModelSpinal muscular atrophy (SMA) is a motor...
Jerry R. Mendell, MDJerry R. Mendell, MD, is an Attending Ne...
Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy—Protocol ...Spinal muscular atrophy (SMA) is a rare ...
Comparative All-Cause Mortality Among a Large Population of Patients With Spinal Muscular Atrophy Versus Matched Con...Introduction: There is little informatio...
Understanding Spinal Muscular Atrophy (SMA)https://www.youtube.com/watch?v=5mI_ZsWk...
CHOP – Spinal Muscular Atrophy (SMA)Why Choose CHOP for SMA Treatment?Being ...